特罗凯治疗复发或转移子宫内膜癌的II期临床实验
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A.
Author information Princess Margaret Hospital, University Health Network, Bras Family Drug Development Program, University of Toronto, Toronto, Ontario, Canada. amit.oza@uhn.on.ca
Abstract
PURPOSE: Epidermal growth factor receptor (EGFR) overexpression is common in endometrial cancers and may have a major role in tumor growth and progression. Erlotinib is an orally active, selective inhibitor of EGFR tyrosine kinase activity.
PATIENTS AND METHODS: A multinomial design two-stage phase II study was performed to evaluate single-agent activity of erlotinib in women with advanced endometrial cancer with recurrent or metastatic disease who were chemotherapy naïve and had received up to one line of prior hormonal therapy. Erlotinib was administered at daily dose of 150 mg. Archival tumor tissue was analyzed for EGFR expression by immunohistochemistry (IHC) and gene amplification by fluorescent in situ hybridization (FISH). Mutational status of EGFR was determined in responders.
RESULTS: Thirty-two of 34 entered patients are assessable for response. Treatment was well tolerated and severe toxicity infrequent, with the only grade 4 toxicity being an elevation of transaminases (AST). There were four confirmed partial responses (PRs; 12.5%; 95% CI, 3.5% to 29%) lasting 2 to 36 months. Fifteen patients had stable disease (SD), with median duration of 3.7 months (range, 2 to 12 months). EGFR expression was analyzed in thirty patients; 19 were positive, nine were negative, and two were not assessable. Of the 19 patients who were EGFR positive, three had PR (16%), seven SD, and eight progressive disease, and one was not assessable. No mutations were identified in responders. FISH showed no correlation of response with gene amplification.
CONCLUSION: Erlotinib is well tolerated with an overall objective response rate of 12.5%. Molecular analysis did not identify EGFR mutations in responders or correlation of response with gene amplification.
我的评论：这些病人经过化疗和内分泌治疗，仍然有12.5%的客观反应率，疾病控制率超过50%（PR+SD），另外EGFR的状态跟疗效没有明显关系，所以在目前缺乏足够靶向药的现实下，经历多线治疗晚期子宫内膜病人可以试试特罗凯。 谢谢楼主的分享！ 祝seacat版主中秋节快乐，谢谢您对大家无私的帮助。 已学习，谢谢 新人，刚刚看到斑竹发的这个帖子，很高兴，虽然还没有搞懂一些问题，需要进一步的学习，但是斑竹提供的这个信息，让我心情大好，谢谢斑竹提供，你辛苦了 【枫】_Z2lZ6 发表于 2015-4-3 23:16
用特罗凯？这是没办法中的办法吗？......SCat，请问下你平常是去哪个网站留意这些前沿信息回来的呀？
www.google.com 你好，我刚刚给你发过消息，就是子宫内膜癌正在使用PD1的病人，我想寻找能够在PD1使用期间联用的靶向，难道可以选择特罗凯吗？
stonezhezhe 发表于 2017-4-24 14:26
你好，我刚刚给你发过消息，就是子宫内膜癌正在使用PD1的病人，我想寻找能够在PD1使用期间联用的靶向，难道 ...
PD-1不要联和特罗凯，间质性肺炎风险高。
要联就联合贝伐珠单抗。
页:
[1]
2